LifeMD price target lowered to $14 from $18 at Lake Street

Lake Street lowered the firm’s price target on LifeMD (LFMD) to $14 from $18 and keeps a Buy rating on the shares. LifeMD lowered its full-year guidance primarily due to temporary challenges in its Rex MD business and higher refund rates in its weight management segment, notes the analyst, who says “softer results and lowered guidance will unfortunately be the storyline.” However, the firm thinks LifeMD is still well-positioned to deliver over the long-term with growing scale, rising profitability, and potential upside from strategic assets, the analyst added.